The Centre has begun cracking down on pharmaceutical manufacturers that fail to meet revised quality standards, with non-compliant companies being asked to shut down unless they upgrade their facilities, said Manoj Joshi, Secretary, Department of Pharmaceuticals

Amid increasing global concerns over Indian pharmaceuticals, India's drug regulator is rigorously addressing high-risk manufacturing sites. This decisive action follows extensive…

Pharma Secretary Manoj Joshi outlines India's commitment to quality reforms and a robust biopharma ecosystem to maintain its global pharmaceutical leadership.